Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Stephen J FreedlandMurilo de Almeida LuzUgo De GiorgiMartin GleaveGeoffrey T GottoChristopher M PieczonkaGabriel P HaasChoung-Soo KimMiguel Ramirez-BackhausAntti RannikkoJamal TaraziSwetha SridharanJennifer SuggYiyun TangRonald F TutroneBalaji VenugopalArnauld VillersHenry H WooFabian ZohrenNeal D ShorePublished in: The New England journal of medicine (2023)
In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis-free survival; enzalutamide monotherapy was also superior to leuprolide alone. The safety profile of enzalutamide was consistent with that shown in previous clinical studies, with no apparent detrimental effect on quality of life. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.).